Collectively, these findings indicate the feasibility of using IL4RPep-1-EVs as nanocarriers for delivering therapeutic agents in treating anaplastic thyroid cancer and other cancers that express IL4R. Here, IL4R is linked to thyroid gland undifferentiated (anaplastic) carcinoma.